Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: A randomized study

Australasian Journal of Dermatology

Volumn 50, Issue 3, 2009, Pages 181-185

  Kaur, Inderjeet ^a   Dogra, Sunil ^a   Narang, Tarun ^b   De, Dipankar ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b GIAN SAGAR MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Comparison; Efficacy; Moderate to severe; Multibacillary leprosy; Side effects; Treatment; Type 2 lepra reaction

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CHLOROQUINE; CLOFAZIMINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; INDOMETACIN; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; PREDNISOLONE; THALIDOMIDE; ZAFIRLUKAST; ZINC;

ACNE; ADULT; AMEBIASIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHINGOID SYNDROME; DERMATOMYCOSIS; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERYTHEMA NODOSUM LEPROSUM; EYE DISEASE; FEMALE; GENERAL CONDITION IMPROVEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOCYTOCLASTIC VASCULITIS; MALE; PEPTIC ULCER; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TREMOR; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA NODOSUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; PREDNISOLONE; PROBABILITY; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; THALIDOMIDE; TREATMENT OUTCOME;

EID: 68349099102     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2009.00534.x     Document Type: Article

References (19)

1. Lockwood DN. The management of erythema nodosum leprosum: current and future options. Lepr. Rev. 1996 67 : 253 9.
2. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int. J. Lepr. Other Mycobact. Dis. 2004 72 : 125 33.
3. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J. Infect. Dis. 1993 168 : 408 14.
4. Pannikar V. The return of thalidomide: new uses and renewed concerns. Lepr. Rev. 2003 74 : 286 8.
5. Lockwood DN, Bryceson A. The return of thalidomide: new uses and renewed concerns: reply. Lepr. Rev. 2003 74 : 290 4.
6. Pereira GF. On thalidomide and WHO policies: reply. Lepr. Rev. 2003 74 : 288 90.
7. Ramu G, Girdhar A. Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazamine. Lepr. India 1979 51 : 497 504. (Pubitemid 10149662)
8. World Health Organization. Leprosy: global situation. Wkly Epidemiol. Rec. 2006 81 : 309 16.
9. Lockwood DN, Vinayakumar S, Stanley JN, Mcadam PW, Colston MJ. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int. J. Lepr. Other Mycobact. Dis. 1993 8 15.
10. Naafs B. Treatment of reactions and nerve damage. Int. J. Lepr. Other Mycobact. Dis. 1996 64 : S21 8.
11. Iyer CG, Languillon J, Ramanujam K, Tarabini-Castellani G, De las Aguas JT, Bechelli LM, Uemura K, Martinez Dominguez V, Sundaresan T. WHO co-ordinated short term double blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull. World Health Organ. 1971 45 : 719 32.
12. Villahermosa LG, Fajardo TT Jr., Abalos RM, Balagon MV, Tan EV, Cellona RV et al. A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. Am. J. Trop. Med. Hyg. 2005 72 : 518 26.
13. Stirling DI. Thalidomide and its impact in dermatology. Semin. Cutan. Med. Surg. 1998 17 : 231 42.
14. Sales AM, de Matos HJ, Nery JA, Duppre NC, Sampaio EP, Sarno EN. Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type 2 reaction in leprosy. Braz. J. Med. Biol. Res. 2007 40 : 243 8.
15. Andre L, Moreira GK. Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int. J. Lepr. Other Mycobact. Dis. 1998 66 : 61 4.
16. Sugumaran DS. Leprosy reactions - complications of steroid therapy. Int. J. Lepr. Other Mycobact. Dis. 1998 66 : 10 5.
17. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. 1996 35 : 969 79.
18. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001 24 : 1050 7.
19. Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch. Dermatol. 1994 130 : 66 9.